These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 24638152

  • 21. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.
    Saxena A, Kapoor J, Meteling B, Morris DL, Bester L.
    Ann Surg Oncol; 2014 Apr; 21(4):1296-303. PubMed ID: 24337647
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.
    Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G.
    Hepatology; 2010 Nov; 52(5):1741-9. PubMed ID: 21038413
    [Abstract] [Full Text] [Related]

  • 24. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE, Monsky WL, Valji K, Hippe DS, Padia SA.
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [Abstract] [Full Text] [Related]

  • 25. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM, Titano JJ, Tabori NE, Pierobon ES, Alshebeeb K, Schwartz M, Facciuto ME, Gunasekaran G, Florman S, Fischman AM, Patel RS, Nowakowski FS, Kim E.
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [Abstract] [Full Text] [Related]

  • 26. Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases.
    Ruohoniemi DM, Zhan C, Wei J, Kulkarni K, Aaltonen ET, Horn JC, Hickey RM, Taslakian B.
    J Vasc Interv Radiol; 2020 Aug; 31(8):1233-1241. PubMed ID: 32741550
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction.
    Gaba RC, Riaz A, Lewandowski RJ, Ibrahim SM, Ryu RK, Sato KT, Omary RA, Salem R.
    J Vasc Interv Radiol; 2010 Aug; 21(8):1213-8. PubMed ID: 20598575
    [Abstract] [Full Text] [Related]

  • 29. Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer.
    Davisson NA, Bercu ZL, Friend SC, Paplomata E, Ermentrout RM, Newsome J, Majdalany BS, Kokabi N.
    J Vasc Interv Radiol; 2020 Jun; 31(6):925-933. PubMed ID: 32307310
    [Abstract] [Full Text] [Related]

  • 30. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM, Schuster DM, Barron BJ, Dhanasekaran R, Lawson DH, Kim HS.
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA, Kim HS.
    J Vasc Interv Radiol; 2010 Feb; 21(2):224-30. PubMed ID: 20022765
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.
    Gordon AC, Gradishar WJ, Kaklamani VG, Thuluvath AJ, Ryu RK, Sato KT, Gates VL, Salem R, Lewandowski RJ.
    J Vasc Interv Radiol; 2014 Oct; 25(10):1523-32, 1532.e1-2. PubMed ID: 25156827
    [Abstract] [Full Text] [Related]

  • 35. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
    Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, Ursic-Bedoya J, Pageaux GP, Mariano-Goulart D, Aho S, Guiu B.
    J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
    [Abstract] [Full Text] [Related]

  • 36. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients.
    Saxena A, Meteling B, Kapoor J, Golani S, Morris DL, Bester L.
    Ann Surg Oncol; 2015 Mar; 22(3):794-802. PubMed ID: 25323474
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.